This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
This new lyophilizer is equipped with systems to best protect high value Active Pharmaceutical Ingredients (APIs) and doubles the lyophilization capacity at the site
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
The drug is being developed at lab scale for the first-line of treatment of Covid-19
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
Subscribe To Our Newsletter & Stay Updated
